Sirtex Medical, a global life sciences company, and Guerbet, a pharmaceutical group dedicated to medical imaging worldwide, are collaborating to advance research in primary and secondary metastatic liver cancer. The objective is to evaluate the unmet clinical need in patients with hepatocellular carcinoma, metastatic colorectal cancer, neuroendocrine tumors and a range of other secondary liver cancers.

Sirtex's chief medical officer, David Cade, said, "Interventional oncology is one of the fastest growing and most exciting areas of innovation in cancer care, giving patients with few or no treatment choices an extended lease on life, while helping maintain their quality of life."

Guerbet and Sirtex share a common vision to advance interventional oncology by developing new approaches in patient care and treatment algorithms that may revolutionize liver cancer therapy.